Russia’s Sputnik V Vaccine Has 92% Efficacy, Interim Analysis Shows

Russia’s coronavirus vaccine Sputnik V has demonstrated 92 percent efficacy based on the first interim analysis that was obtained 21 days after volunteers received the first injection, according to the press release published in the official Twitter account of the vaccine.

As many as 40,000 volunteers are currently taking part in the double-blind, randomized, placebo-control phase 3 of the clinical trials. Over 20,000 of them have already received the first component of the vaccine, while over 16,000 volunteers have received both the first and the second doses.

​”As of November 11, no unexpected adverse events were identified as part of the research. Some of those vaccinated had short-term minor adverse events such as pain at the injection site, flu-like syndrome including fever, weakness, fatigue, and headache,” the press release read on.

Observation of the volunteers will continue for six months, and after that, the final report will be presented, according to the press release.

Russia registered the world’s first COVID-19 vaccine, Sputnik V, on 11 August. It was developed by the Gamaleya Research Institute and produced in cooperation with the Russian Direct Investment Fund (RDIF). While stage three clinical trials of the vaccine have been underway in Russia, trials have also been announced in the United Arab Emirates, India, Venezuela, and Belarus.

Leave comment

Your email address will not be published. Required fields are marked with *.